| Quarterly Results (Unaudited) | 
 16. Quarterly Results (Unaudited) 
  
Selected quarterly financial data for
2016 and 2015 are contained in the Condensed Interim Financial Data table below. 
  
    | ($ in thousands except per share amounts) | 
      | 
    4th Q | 
      | 
      | 
    3rd Q | 
      | 
      | 
    2nd Q | 
      | 
      | 
    1st Q | 
      | 
 
    | 2016 | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
 
    | Grant Revenues | 
      | 
    $ | 
    - | 
      | 
      | 
    $ | 
    - | 
      | 
      | 
    $ | 
    - | 
      | 
      | 
    $ | 
    - | 
      | 
 
    | Research and development | 
      | 
      | 
    93,876 | 
    (1) | 
      | 
      | 
    2,093 | 
      | 
      | 
      | 
    2,368 | 
      | 
      | 
      | 
    3,342 | 
      | 
 
    | General and administrative | 
      | 
      | 
    510 | 
      | 
      | 
      | 
    (199 | 
    ) | 
      | 
      | 
    1,836 | 
      | 
      | 
      | 
    1,992 | 
      | 
 
    | Total costs and expenses | 
      | 
      | 
    94,386 | 
      | 
      | 
      | 
    1,894 | 
      | 
      | 
      | 
    4,204 | 
      | 
      | 
      | 
    5,334 | 
      | 
 
    | Operating loss | 
      | 
      | 
    (94,386 | 
    ) | 
      | 
      | 
    (1,894 | 
    ) | 
      | 
      | 
    (4,204 | 
    ) | 
      | 
      | 
    (5,334 | 
    ) | 
 
    | Other income (expense), net | 
      | 
      | 
    (762 | 
    ) | 
      | 
      | 
    13 | 
      | 
      | 
      | 
    977 | 
      | 
      | 
      | 
    1,322 | 
      | 
 
    | Income tax benefit (provision) | 
      | 
    $ | 
    29,394 | 
      | 
      | 
    $ | 
    - | 
      | 
      | 
    $ | 
    - | 
      | 
      | 
    $ | 
    - | 
      | 
 
    | Net (loss) income | 
      | 
      | 
    (65,754 | 
    ) | 
      | 
      | 
    (1,881 | 
    ) | 
      | 
      | 
    (3,227 | 
    ) | 
      | 
      | 
    (4,012 | 
    ) | 
 
    | Basic (loss) earnings per common share | 
      | 
    $ | 
    (0.10 | 
    ) | 
      | 
    $ | 
    (0.00 | 
    ) | 
      | 
    $ | 
    (0.00 | 
    ) | 
      | 
    $ | 
    (0.01 | 
    ) | 
 
    | (Loss) earnings per common share assuming dilution | 
      | 
    $ | 
    (0.10 | 
    ) | 
      | 
    $ | 
    (0.00 | 
    ) | 
      | 
    $ | 
    (0.00 | 
    ) | 
      | 
    $ | 
    (0.01 | 
    ) | 
 
    |   | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
 
    | 2015 | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
      | 
 
    | Grant Revenues | 
      | 
    $ | 
    - | 
      | 
      | 
    $ | 
    24 | 
      | 
      | 
    $ | 
    27 | 
      | 
      | 
    $ | 
    27 | 
      | 
 
    | Research and development | 
      | 
      | 
    41,578 | 
    (2) | 
      | 
      | 
    2,177 | 
      | 
      | 
      | 
    1,946 | 
      | 
      | 
      | 
    1,560 | 
      | 
 
    | General and administrative | 
      | 
      | 
    2,795 | 
      | 
      | 
      | 
    1,437 | 
      | 
      | 
      | 
    1,898 | 
      | 
      | 
      | 
    635 | 
      | 
 
    | Total costs and expenses | 
      | 
      | 
    44,373 | 
      | 
      | 
      | 
    3,614 | 
      | 
      | 
      | 
    3,844 | 
      | 
      | 
      | 
    2,195 | 
      | 
 
    | Operating loss | 
      | 
      | 
    (44,373 | 
    ) | 
      | 
      | 
    (3,590 | 
    ) | 
      | 
      | 
    (3,817 | 
    ) | 
      | 
      | 
    (2,168 | 
    ) | 
 
    | Other income (expense), net | 
      | 
      | 
    (1,376 | 
    ) | 
      | 
      | 
    3,082 | 
      | 
      | 
      | 
    1,246 | 
      | 
      | 
      | 
    (14,374 | 
    ) | 
 
    | Income tax benefit (provision) | 
      | 
      | 
    15,300 | 
      | 
      | 
      | 
    - | 
      | 
      | 
      | 
    (52 | 
    ) | 
      | 
      | 
    - | 
      | 
 
    | Net (loss) income | 
      | 
    $ | 
    (30,449 | 
    ) | 
      | 
    $ | 
    (508 | 
    ) | 
      | 
    $ | 
    (2,623 | 
    ) | 
      | 
    $ | 
    (16,542 | 
    ) | 
 
    | Basic (loss) earnings per common share | 
      | 
    $ | 
    (0.05 | 
    ) | 
      | 
    $ | 
    (0.00 | 
    ) | 
      | 
    $ | 
    (0.00 | 
    ) | 
      | 
    $ | 
    (0.03 | 
    ) | 
 
    | (Loss) earnings per common share assuming dilution | 
      | 
    $ | 
    (0.05 | 
    ) | 
      | 
    $ | 
    (0.01 | 
    ) | 
      | 
    $ | 
    (0.01 | 
    ) | 
      | 
    $ | 
    (0.04 | 
    ) | 
 
 
  
    | (1) | 
      | 
    Includes impairment charge for the company’s IPR&D asset of $92,369,000 | 
 
    |   | 
      | 
      | 
 
    | (2) | 
      | 
    Includes impairment charge for the company’s IPR&D asset of $38,665,000 | 
 
 
 |